General Information of Drug (ID: DM1SMAI)

Drug Name
Eperisone
Synonyms EMPP; Myonal; Myorelark; E-0646; E-2000; E-646; Eperisone (transdermal patch); Eperisone (oral), Eisai; Eperisone (transdermalpatch), Eisai; E-2000 (oral), Eisai; E-2000 (transdermal patch), Eisai
Indication
Disease Entry ICD 11 Status REF
Muscle spasm MB47.3 Phase 3 [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 259.399
Logarithm of the Partition Coefficient (xlogp) 3.8
Rotatable Bond Count (rotbonds) 5
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 2
Chemical Identifiers
Formula
C17H25NO
IUPAC Name
1-(4-ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one
Canonical SMILES
CCC1=CC=C(C=C1)C(=O)C(C)CN2CCCCC2
InChI
InChI=1S/C17H25NO/c1-3-15-7-9-16(10-8-15)17(19)14(2)13-18-11-5-4-6-12-18/h7-10,14H,3-6,11-13H2,1-2H3
InChIKey
SQUNAWUMZGQQJD-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
3236
ChEBI ID
CHEBI:77070
CAS Number
64840-90-0
DrugBank ID
DB08992
TTD ID
D0P8TS
INTEDE ID
DR0585
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Voltage-gated calcium channel (Cav) TTCRJKY NOUNIPROTAC Modulator [2]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [3]
Cytochrome P450 2J2 (CYP2J2) DERSX5P CP2J2_HUMAN Substrate [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT02040415) Phase 3 Study to Evaluate the Efficacy and Safety of DW-1030 and Eperisone HCl in Acute Back Pain Patients. U.S. National Institutes of Health.
2 Suppression of calcium current in a snail neurone by eperisone and its analogues. Eur J Pharmacol. 1989 Sep 22;168(3):299-305.
3 Characterization of human cytochrome P450 enzymes involved in the biotransformation of eperisone. Xenobiotica. 2009 Jan;39(1):1-10.